Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07601841 · ClinicalTrials.gov registry record · NA

Light Therapy to Improve Sleep in TBI: Sleep-active Biomarkers and Glymphatic Function

A NA study, sponsored by Oregon Health and Science University.

Recruiting
Registry status
NA
Development phase
300
Enrollment target

NCT07601841: Recruiting NA study, sponsored by Oregon Health and Science University.

NCT07601841 is a NA study that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 300 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07601841, a NA study, is actively recruiting participants, sponsored by Oregon Health and Science University.

RECRUITING
Registry status
NA
Development phase
300 participants
Enrollment target

Study Summary

This is a clinical trial designed to examine how improved sleep through morning bright light therapy is improving downstream key physiologic processes related to brain health, i.e., mitochondrial function, systemic inflammation, and glymphatic function. All proposed methodology is already approved in other IRB applications.

Primary Outcome

The primary outcome defines the pre- to post-intervention change in inflammatory target expression using NULISA proteomics (reporting proteins as NPQ relative units).

Interventions

  • DEVICE Morning Bright Light Therapy
  • DEVICE Negative Ion Generator Therapy

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2025-12-12
Est. Completion 2030-09-30
Phase NA

What NCT07601841 shows while recruiting

NCT07601841 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (79% lower).

The record links to 0 conditions, and to 2 interventions - of which Morning Bright Light Therapy is the first listed.

NCT07601841 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07601841 about?

NCT07601841 is a clinical study titled "Light Therapy to Improve Sleep in TBI: Sleep-active Biomarkers and Glymphatic Function". This is a clinical trial designed to examine how improved sleep through morning bright light therapy is improving downstream key physiologic processes related to brain health, i.e., mitochondrial function, systemic inflammation, and glymphatic function. All proposed methodology is already approved i...

What is the current status of trial NCT07601841?

This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2025-12-12. Estimated completion is 2030-09-30.

What interventions are being tested in trial NCT07601841?

The interventions under investigation include: Morning Bright Light Therapy (DEVICE), Negative Ion Generator Therapy (DEVICE).

Who is sponsoring clinical trial NCT07601841?

This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07601841's enrollment target sits among peer trials

300 330th of 2000 higher than 1,630 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07601841, the US trial registry maintained by the National Library of Medicine. NCT07601841 (mid enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.